Please assess the completion status of the following clinical trial:

Trial Title: Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Breast cancer with evidence of unresectable, locally recurrent, or metastatic disease.~* Tumors over-expressing Her-2~* Candidate for treatment with docetaxel/trastuzumab~Exclusion Criteria:~* Histology of inflammatory carcinoma~* AST and/or ALT \>1.5 x ULN concomitant with ALP \>2.5 x ULN

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Combination of SU011248 (37.5 mg once daily \[Schedule 2/1\]) with docetaxel (75 mg/m2 every 3 weeks) and trastuzumab (therapeutic dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).